sellModerate cluster of 4
Primit Parikh sold $51k of TGAN
President and COO at Transphorm, Inc.. 8,927 shares at an average of $5.67, traded Nov 17, 2022, filed Nov 21, 2022.
Warning score
42Value
$51k
8,927 shares
Holdings after
237,558
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- +7Trade size$51k at market
- 0Share of holdings soldSold 3.6% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-22-058115, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2022 | SOpen-market sale Common Stock | -8,927 | $5.67 | $51k | 237,558 | Nov 21, 2022 |
Related signals
Other insiders at Transphorm, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | TGANsell Transphorm, Inc. | KKR Phorm Investors L.P. owner | $125M 24,411,968 shares | -100% | |
| 3Weak | Transphorm, Inc. | Katharina G. McFarland director | $20k 3,996 shares | -5% | |
| 3Weak | Transphorm, Inc. | Kelly Smales director | $20k 3,996 shares | -5% | |
| 3Weak | Transphorm, Inc. | Katharina G. McFarland director | $4,074 840 shares | -1% | |
| 3Weak | Transphorm, Inc. | Kelly Smales director | $2,304 475 shares | -1% | |
| 0Weak | Transphorm, Inc. | Kelly Smales director | $3,753 766 shares | -1% | |
| 45Moderate | Transphorm, Inc. | Primit Parikh PRESIDENT AND CEO | $29k 6,000 shares | -1% | |
| 10Weak | Transphorm, Inc. | Katharina G. McFarland director | $19k 3,996 shares | -5% | |
| 10Weak | Transphorm, Inc. | Kelly Smales director | $19k 3,996 shares | -5% | |
| 3Weak | Transphorm, Inc. | Katharina G. McFarland director | $4,015 833 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.